We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
9.50 | 0.73% | 1,309.50 | 1,309.00 | 1,310.00 | 1,309.50 | 1,300.00 | 1,300.00 | 156,484 | 08:14:44 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1889 | 11.01 | 53.89B |
Date | Subject | Author | Discuss |
---|---|---|---|
15/11/2024 14:56 | Averaged down, as this is simply nuts. Panic and shorters | dope007 | |
15/11/2024 14:53 | It will bounce imho. Just a bit of patience needed. | pander45 | |
15/11/2024 14:50 | Three year low, also way below what they were 30 years ago, incredible. | montyhedge | |
15/11/2024 14:50 | Fell more than larger vaccine makers and those involved with the covid vaccine. Absolutely laughable | dope007 | |
15/11/2024 14:43 | Price collapse is hard to believe! | tradermichael | |
15/11/2024 14:21 | Panache. Wonder if you might see £11? The uncertainty is only going to grow for a while. | purchaseatthetop | |
15/11/2024 13:59 | Pharmaceutical companies were the main FTSE 100 losers. GSK was down 3.2%, Croda International lost 2.9%, and AstraZeneca was down 2.5%. "The announcement of vaccine-sceptic Robert F Kennedy Junior as health secretary pick for the incoming Trump administration has spooked investors in the sector, with US drug companies also seeing their shares come under significant pressure overnight," explained Mould. "The impact on the sector is hard to judge fully at this stage but, at the very least, it will cause a good deal of uncertainty.". | fuji99 | |
15/11/2024 13:03 | Please beware of PURCHASEATTHETOP(RIC RICHARD BOBARTH news article www.mirror.co.uk/new | antonagis | |
15/11/2024 12:45 | FYI to people on here - purchaseatthetop is this guy. Do not engage especially if he tries to DM you hTTps://www.mirror.c | dplewis1 | |
15/11/2024 12:15 | Nothing like making your health supreme somebody who says part of his brain was eaten by a worm… | purchaseatthetop | |
15/11/2024 12:06 | Indeed it has. Got my 13 quid. | pander45 | |
15/11/2024 11:54 | I'll add a few more (way too many atm though) when the US opens | panache1 | |
15/11/2024 11:23 | dplewis1 - 09 Oct 2024 - 18:35:11 - 33395 of 33674 Glaxosmithkline - The recovery - GSK Pander isn't getting his 13 quid that's for sure Seems the market has decided otherwise! | purchaseatthetop | |
15/11/2024 11:18 | 1033 GMT - The vaccine sector is under pressure after the nomination of Robert F. Kennedy Jr. as U.S.'s Health Secretary, but the market reaction looks overdone, Bryan Garnier Research analysts write. Kennedy is feared for his anti-vax positions, the analysts say. Shares in Pfizer, GSK, Moderna and BioNTech all dropped in Thursday's U.S. session and the sell-off has continued in Europe. Bavarian Nordic shares are down 16%, Valneva shares 6.1% lower with GSK and Sanofi both down 2.7%. However, the analysts believe the vaccine recommendation process has rigid structures in place, and U.S. governmental action will likely focus more on increased transparency and public information on vaccine risks and benefits. "We thus expect no impact on Valneva and Bavarian Nordic business near-term." | dplewis1 | |
15/11/2024 10:28 | My post yesterday was before that announcement, d'oh! However I'm not talking about daily movements, just look at the longer term chart. | bountyhunter | |
15/11/2024 10:11 | got a few more at 13.11 | supermarky | |
15/11/2024 10:01 | It's a buy at these levels imho. | pander45 | |
15/11/2024 09:50 | Which is why I am buying......I presume you will wait till it's back to £16, like all amateurs? | cumnor | |
15/11/2024 09:41 | Oh,dear this is plumbing | thomstar | |
15/11/2024 09:14 | Post-election jitters. GSK is expected to report earnings of 91p per share this year, and that then rises to 143p in 2025 and 159p in 2026. | tradermichael | |
15/11/2024 09:13 | I use this site as a news sentiment check and it all looks good news for GSK but the share price is not reacting | hatfullofsky |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions